Modipafant, a new PAF antagonist: pharmacokinetics and disposition in rat, dog and man

References

• Alabaster V. A., Keir R. F., Parry M. J., de Souza R. N. UK-74,505: a novel and selective PAF antagonist, exhibits potent and long lasting activity in vivo. Agents and Action 1991; 34(suppl.)221–227, In New Drugs for Asthma Therapy edited by G. P. Anderson, S. D. Chapman, and J. Morley.
   PubMedGoogle Scholar
• Beresford A. P., Macrae P. V., Stopher D. A. Metabolism of amlodipine in the rat and dog: a species difference. Xenobiotica 1988; 18: 169–182
   PubMed Web of Science ®Google Scholar
• Braquet P., Touqui L., Shen T. Y., Vargaftig B. B. Perspectives in platelet-activating factor research. Pharmacological Reviews 1987; 39: 97–145
   PubMed Web of Science ®Google Scholar
• Cooper K., Fray M. J., Richardson K., Steele J. A novel and highly potent dihydropyridine PAF antagonist: synthesis and structure-activity relationship. Journal Lipid Mediators 1990; 2: 212–218
   Google Scholar
• Cooper K., Fray M. J., Parry M. J., Richardson K., Steele J. 1,4-Dihydropyridines as antagonists of platelet activating factor. 1. Synthesis and structure activity relationships of 2-(4-heterocyclyl) phenyl derivatives. Journal of Medicinal Chemistry 1992; 35: 3115–3129
   PubMed Web of Science ®Google Scholar
• Dayton P. G., Israeili Z. H., Henderson J. D. Elimination of drugs by passive diffusion from blood to intestinal lumen: factors influencing non-biliary secretion by the biliary tract. Drug Metabolism Reviews 1983; 14: 1193–1206
   PubMed Web of Science ®Google Scholar
• Demopoulos C. A., Pinckard R. N., Hanahan D. J. Platelet-activating factor, evidence for 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine as the active component (a new class of lipid mediators). Journal Biological Chemistry 1979; 254: 9350–9358
   Google Scholar
• Helander H. F., Ramsay C. H., Regand C. G. Localisation of omeprazole and metabolites in the mouse. Scandinavian Journal of Gastroenterology 1985; 20(suppl 108)95–104
   Google Scholar
• Humphrey M. J., Jevons S., Tarbit M. H. Pharmacokinetic evaluation of UK-49,858. A metabolically stable triazole antifungal drug, in animals and man. Antimicrobial Agents and Chemotherapy 1985; 28: 648–653
   PubMed Web of Science ®Google Scholar
• Kobliakov V., Popova N., Rossie L. Regulation of the expression of the sex specific isoforms of cytochrome P-450 in rat liver. European Journal of Biochemistry 1991; 195: 585–591
   PubMedGoogle Scholar
• Koltai M., Hosford D., Guinot P., Esanu A., Braquet P. Platelet activating factor (PAF). A review of its effects, antagonists and possible future clinical applications (Part I). Drugs 1991a; 42: 9–29
   PubMed Web of Science ®Google Scholar
• Koltai M., Hosford D., Guinot P., Esanu A., Braquet P. Platelet activating factor (PAF). A review of its effects, antagonists and possible future clinical applications (Part II). Drugs 1991b; 42: 174–204
   PubMedGoogle Scholar
• Kuttert L. M., Hui K. P., Uthayarkumar S., Bunk W., Newland A. C., Uden S., Barnes N. C. Effect of the platelet-activating factor antagonist UK-74,505 on early and late response to allergen. American Review of Respiratory Diseases 1993; 147: 82–86
   PubMedGoogle Scholar
• Kuitert L. M., Angus R. M., Barnes N. C., Barnes P. J., Bone M. F., Chung K. F., Fairfax A. J., Higenbotham T. W., Connor B. J., Piotroska B., Rogniecki J., Uden S., Walter E. H., Willard C. J. Effect of a novel potent platelet activating factor antagonist, Modipafant. American Journal of Respiratory Critical are Medicine 1995; 151: 1331–1335
   PubMed Web of Science ®Google Scholar
• Niwa T., Tokuma Y., Noguchi H. Oxidation of nilvadipine, a new dihydropyridine calcium antagonist, to the corresponding pyridine by rat liver microsomes. Xenobiotica 1988; 18: 217–224
   PubMed Web of Science ®Google Scholar
• Parry M. J., Alabaster V. A., Gheeseman H. E., Cooper K., de Souza R. N., Keir R. F. Pharmacological profile of UK-74,505, a novel and selective PAF antagonist with potent and prolonged oral activity. Journal of Lipid Mediators and Cell Signalling 1994; 10: 251–268
   PubMedGoogle Scholar
• Parry M. J., Alabaster V. A., Cheeseman H. E., de Souza R. N., Kier R. F. In vitro and in vivo profile of UK-74,505: a novel, highly potent and selective dihydropyridine PAF antagonist. Journal of Lipid Mediators and Cell Signalling 1990; 2: 181–186
   Google Scholar
• Paton W. D. M., Rang H. P. A kinetic approach to mechanism of drug action. Advances in Drug Research 1966; 3: 57–80
   Google Scholar
• Pons F., Rossi A. G., Norman K. E., Williams T. J., Nourshargh S. Role of platelet-activating factor (PAF) in platelet accumulation in rabbit skin: effect of the novel long-acting PAF antagonist, UK-74,505. British Journal Pharmacology 1993; 109: 234–242
   PubMedGoogle Scholar
• Ritschel W. A., Adolph S., Denson D. D. Ion trapping of meperidine: influence of antacid treatments on serum and gastric fluid concentration. Methods and Findings in Experimental Clinical Pharmacology 1990; 12: 47–51
   PubMed Web of Science ®Google Scholar
• Smith D. A. Species differences in metabolism and pharmacokinetics; are we close to an understanding. Drug Metabolism Reviews 1991; 23: 355–373
   PubMed Web of Science ®Google Scholar
• Stopher D., McClean S. An improved method for the determination of distribution coefficients. Journal of Pharmacy and Pharmacology 1990; 42: 144
   PubMed Web of Science ®Google Scholar
• Tsujimoto A., Nakashima T., Tanino S., Dohi T., Kurogochi Y. Tissue distribution of [3H] Nicotine in dogs and rhesus monkeys. Toxicology and Applied Pharmacology 1975; 32: 21–31
   PubMed Web of Science ®Google Scholar
• Yuge T., Hase T., Takeyanagi Y., Kamasuka T., Amemiya K., Horiba M. Pharmacokinetic studies of mabuterol, a new selective beta-2 stimulant. Arzneimittel Forschung 1984; 34: 1659–67
   PubMedGoogle Scholar